Jean Michel Molina

Summary

Country: France

Publications

  1. pmc Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe?
    Jean Michel Molina
    INSERM U941, University of Paris Diderot, Sorbonne Paris Cité, Paris, France
    BMC Med 11:186. 2013
  2. doi request reprint Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies/ml or less: week 48 phase III analysis
    Jean Michel Molina
    University of Paris Diderot, Paris 7 and Department of Infectious Diseases, Saint Louis Hospital, Paris, France
    AIDS 27:889-97. 2013
  3. pmc Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
    Valrie Martinez
    Service de Mdecine Interne et Immunologie Clinique, Assistance publique Hpitaux de Paris, INSERM UMR_S 996, Universit Paris Sud, Hpital Antoine Bclre, 157 rue de la Porte de Trivaux, 92141 Clamart, France
    BMC Res Notes 5:180. 2012
  4. doi request reprint Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
    Jean Michel Molina
    Hôpital Saint Louis and University of Paris Diderot, Paris, France
    Lancet Infect Dis 12:27-35. 2012
  5. doi request reprint Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance
    Jean Michel Molina
    Service des Maladies Infectieuses et Tropicales, Hôpital Saint Louis and University of Paris Diderot, Paris 7, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
    J Antimicrob Chemother 64:398-410. 2009
  6. doi request reprint Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
    Jean Michel Molina
    Department of Infectious Diseases, Saint Louis Hospital and University of Paris Diderot, Paris, France
    Lancet 378:238-46. 2011
  7. ncbi request reprint Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3
    Jean Michel Molina
    Assistance Publique Hopitaux de Paris, Department of Infectious Diseases, Hopital St Louis, Paris, France
    J Acquir Immune Defic Syndr 46:24-31. 2007
  8. doi request reprint Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119)
    Jean Michel Molina
    Assistance Publique Hopitaux de Paris, Hopital Saint Louis, France
    J Infect Dis 200:206-15. 2009
  9. ncbi request reprint Darunavir (TMC114): a new HIV-1 protease inhibitor
    Jean Michel Molina
    Assistance Publique Hôpitaux de Paris and University of Paris 7, Department of Infectious Diseases, Hopital St Louis, Paris, France
    Expert Opin Pharmacother 8:1951-64. 2007
  10. doi request reprint Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study
    Jean Michel Molina
    Department of Infectious Diseases, Hopital Saint Louis 1, Av C Vellefaux, 75475 Paris, Cedex 10, France
    J Acquir Immune Defic Syndr 53:323-32. 2010

Detail Information

Publications123 found, 100 shown here

  1. pmc Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe?
    Jean Michel Molina
    INSERM U941, University of Paris Diderot, Sorbonne Paris Cité, Paris, France
    BMC Med 11:186. 2013
    ..Alternatives to a daily oral PrEP regimen are being explored. ..
  2. doi request reprint Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies/ml or less: week 48 phase III analysis
    Jean Michel Molina
    University of Paris Diderot, Paris 7 and Department of Infectious Diseases, Saint Louis Hospital, Paris, France
    AIDS 27:889-97. 2013
    ..Efavirenz) trials...
  3. pmc Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
    Valrie Martinez
    Service de Mdecine Interne et Immunologie Clinique, Assistance publique Hpitaux de Paris, INSERM UMR_S 996, Universit Paris Sud, Hpital Antoine Bclre, 157 rue de la Porte de Trivaux, 92141 Clamart, France
    BMC Res Notes 5:180. 2012
    ..In HIV and hepatitis C virus (HCV) coinfected patients, the role of antiretroviral therapy (ART) on hepatic steatosis (HS) remains controversial...
  4. doi request reprint Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
    Jean Michel Molina
    Hôpital Saint Louis and University of Paris Diderot, Paris, France
    Lancet Infect Dis 12:27-35. 2012
    ..We aimed to compare the efficacy and safety of elvitegravir with raltegravir, another HIV-1 integrase inhibitor, in patients in whom previous antiretroviral treatment failed...
  5. doi request reprint Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance
    Jean Michel Molina
    Service des Maladies Infectieuses et Tropicales, Hôpital Saint Louis and University of Paris Diderot, Paris 7, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
    J Antimicrob Chemother 64:398-410. 2009
    ....
  6. doi request reprint Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
    Jean Michel Molina
    Department of Infectious Diseases, Saint Louis Hospital and University of Paris Diderot, Paris, France
    Lancet 378:238-46. 2011
    ..We aimed to assess the efficacy, safety, and tolerability of rilpivirine versus efavirenz, each combined with tenofovir-disoproxil-fumarate and emtricitabine...
  7. ncbi request reprint Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3
    Jean Michel Molina
    Assistance Publique Hopitaux de Paris, Department of Infectious Diseases, Hopital St Louis, Paris, France
    J Acquir Immune Defic Syndr 46:24-31. 2007
    ..To examine the efficacy and safety of the selected darunavir/r dose further, additional patients were analyzed...
  8. doi request reprint Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119)
    Jean Michel Molina
    Assistance Publique Hopitaux de Paris, Hopital Saint Louis, France
    J Infect Dis 200:206-15. 2009
    ..Interleukin (IL)-2 increases CD4 T cell counts when combined with antiretroviral therapy (ART). Whether IL-2 alone can increase CD4 cell counts is unknown...
  9. ncbi request reprint Darunavir (TMC114): a new HIV-1 protease inhibitor
    Jean Michel Molina
    Assistance Publique Hôpitaux de Paris and University of Paris 7, Department of Infectious Diseases, Hopital St Louis, Paris, France
    Expert Opin Pharmacother 8:1951-64. 2007
    ..This article reviews the presently available data on darunavir, its pharmacology, pharmacokinetics, drug-drug interactions and clinical trial results, as well as examining darunavir from a health economic perspective...
  10. doi request reprint Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study
    Jean Michel Molina
    Department of Infectious Diseases, Hopital Saint Louis 1, Av C Vellefaux, 75475 Paris, Cedex 10, France
    J Acquir Immune Defic Syndr 53:323-32. 2010
    ..Once-daily atazanavir/ritonavir demonstrated similar antiviral efficacy to twice-daily lopinavir/ritonavir over 48 weeks, with less gastrointestinal disturbance and a better lipid profile, in treatment-naive patients...
  11. doi request reprint Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial
    Sebastien Gallien
    Department of Infectious Diseases, Assistance Publique Hopitaux de Paris, Saint Louis Hospital, Paris, France
    J Antimicrob Chemother 66:2099-106. 2011
    ..To assess the sustainable efficacy and safety of a switch from enfuvirtide to raltegravir in patients with multidrug-resistant HIV infection...
  12. doi request reprint Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use
    Anders Boyd
    INSERM UMR S707, Paris, France
    Antivir Ther 15:963-74. 2010
    ..The effect of TDF on liver fibrosis in 148 HIV-HBV-coinfected patients was prospectively evaluated using Fibrometer∆ scores and liver biopsies in a subset of patients...
  13. ncbi request reprint Development of a real-time polymerase-chain-reaction assay for quantitative detection of Enterocytozoon bieneusi DNA in stool specimens from immunocompromised patients with intestinal microsporidiosis
    Jean Menotti
    Laboratory of Parasitology Mycology, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, and Faculté de Médecine Lariboisière Saint Louis, Universite Paris VII, Paris, France
    J Infect Dis 187:1469-74. 2003
    ..In conclusion, this real-time PCR assay is a reliable tool for quantitation of E. bieneusi DNA in stool specimens and for the monitoring of treatment efficacy...
  14. pmc Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial
    Lauriane Goldwirt
    Department of Clinical Pharmacy, Bicetre Hospital, Assistance Publique Hopitaux de Paris, and University Paris 11, Le Kremlin Bicetre, France
    Antimicrob Agents Chemother 55:3613-5. 2011
    ..49, 0.76, and 0.67 and 0.82, 0.68, and 0.64 for tipranavir and darunavir, respectively. The virologic consequences of these drug interactions have yet to be determined...
  15. ncbi request reprint Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial
    Jean Michel Molina
    Assistance Publique Hopitaux de Paris, Paris, France
    J Infect Dis 191:830-9. 2005
    ..We assessed a once-daily combination to simplify therapy in patients infected with human immunodeficiency virus type 1 (HIV-1)...
  16. doi request reprint Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy
    Juliette Pavie
    Saint Louis Hospital, Assistance Publique Hopitaux de Paris, Department of Infectious Diseases, University of Paris Diderot Paris 7, France
    J Antimicrob Chemother 66:2372-8. 2011
    ..Limited data are available on the use of unboosted atazanavir in combination with nucleoside reverse transcriptase inhibitors (NRTIs) in treatment-experienced HIV-infected patients...
  17. ncbi request reprint Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial)
    Jean Michel Molina
    Assistance Publique Hopitaux de Paris, Hopital Saint Louis, Department of Infectious Diseases, University of Paris 7, France
    Antivir Ther 12:417-22. 2007
    ..Once-daily combination therapy with emtricitabine, didanosine and efavirenz has been highly effective in clinical trials but its long-term efficacy and safety has not been previously reported...
  18. ncbi request reprint Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV
    Karine Lacombe
    INSERM U707, Paris, France
    AIDS 20:419-27. 2006
    ..Little is know about the determinants of liver fibrosis progression and genomic variability in hepatitis B virus (HBV) in HIV/HBV-coinfected patients...
  19. doi request reprint Prevalence of opportunistic intestinal parasitic infections among HIV-infected patients with low CD4 cells counts in France in the combination antiretroviral therapy era
    Juliette Pavie
    Department of Infectious Diseases, Saint Louis Hospital and University of Paris Diderot Paris 7, 1 avenue Claude Vellefaux, 75010 Paris, France
    Int J Infect Dis 16:e677-9. 2012
    ....
  20. ncbi request reprint Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial
    Jean Michel Molina
    Department of Infectious Diseases, Saint Louis Hospital, Paris, France
    J Infect Dis 191:840-7. 2005
    ..The antiviral efficacy of didanosine in patients experiencing virological failure is not well known...
  21. doi request reprint Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy
    Erika F Silva
    Department of Infectious Diseases, AP HP, Hopital Saint Louis, University of Paris Diderot Paris, France
    J Infect Dis 208:892-7. 2013
    ..002), hsCRP level (-46% vs +15%; P < .0001), and D-dimer level (-40% vs +6%; P < .0001). At week 48, there was a reproducible decrease in levels of all biomarkers in the DS arm. ..
  22. doi request reprint Incidence and risk factors of thrombocytopenia in patients receiving intermittent antiretroviral therapy: a substudy of the ANRS 106-window trial
    Marie Anne Bouldouyre
    Department of Infectious Diseases, Hopital Saint Louis, Assistance Publique Hôpitaux de Paris and University of Paris Diderot Paris 7, France
    J Acquir Immune Defic Syndr 52:531-7. 2009
    ..Incidence and risk factors for thrombocytopenia in patients discontinuing highly active antiretroviral therapy (HAART) have not been fully investigated...
  23. ncbi request reprint Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    Antivir Ther 11:693-9. 2006
    ..To determine the potential impact of reverse transcriptase (RT) mutations, other than those currently known to confer nucleoside reverse transcriptase inhibitors (NRTIs) resistance, on the virological response to didanosine (ddl)...
  24. ncbi request reprint A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks
    Jean Michel Molina
    Hopital Saint Louis, AP HP, and University of Paris 7, Paris, France
    AIDS Res Hum Retroviruses 23:1505-14. 2007
    ..LPV/r QD resulted in virologic response similar to LPV/r BID through 96 weeks in antiretroviral-naive subjects. Adherence was significantly higher in the QD group...
  25. ncbi request reprint Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial
    Christophe Piketty
    Department of Immunology, Hôpital Georges Pompidou, Assistance Publique Hopitaux de Paris, Paris, France
    Antivir Ther 11:213-21. 2006
    ..Ritonavir (RTV)-boosted atazanavir (ATV) and tenofovir disoproxil fumarate (TDF-DF) are promising in highly experienced patients because of their pharmacokinetic profile, activity, safety and resistance properties...
  26. doi request reprint Antiretroviral therapy initiation in France: adherence to national guidelines and outcome
    Vatthanaphone Latthaphasavang
    1Department of Infectious Diseases, Saint Louis Hospital, AH HP, and University of Paris Diderot, Paris, France
    J Int Assoc Physicians AIDS Care (Chic) 11:40-6. 2012
    ..Retrospective study of all patients who started antiretroviral therapy (ART) in 2007 in a single center in Paris, with baseline characteristics and 1-year outcome, to assess adherence to national guidelines...
  27. pmc Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients
    Karine Lacombe
    INSERM UMR S707, Paris, France
    Antivir Ther 13:705-13. 2008
    ..Characteristics and factors influencing viral decay under tenofovir (TDF) and adefovir (ADV) need to be determined in HIV-HBV-coinfected patients...
  28. doi request reprint Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen
    Constance Delaugerre
    Virology Department, Saint Louis Hospital APHP, Paris, France
    AIDS 22:1809-13. 2008
    ..Limited data are available on resistance pattern emerging in patients failing DRV/r and on subsequent remaining protease inhibitor options...
  29. pmc Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy
    Sidonie Lambert-Niclot
    Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, Paris, France
    Antimicrob Agents Chemother 54:4910-3. 2010
    ..The median darunavir seminal plasma concentration was close to the blood plasma free fraction, demonstrating a good penetration of darunavir into the male genital tract...
  30. doi request reprint Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen
    Constance Delaugerre
    Virology Department, INSERM U941 Paris 7 Diderot University, Saint Louis Hospital APHP, Paris, France
    AIDS 24:2391-5. 2010
    ..In vitro, integrase inhibitors reduce proviral DNA levels and rapidly increase 2-long-terminal repeat (LTR) circle levels. We examined the effect of raltegravir on the time course of HIV-1 DNA forms in patients with controlled viremia...
  31. pmc High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial
    Caroline Barau
    Department of Clinical Pharmacy, Bicetre Hospital, Assistance Publique Hopitaux de Paris, 78 rue du General Leclerc, 94275 Le Kremlin Bicetre, France
    Antimicrob Agents Chemother 54:937-9. 2010
    ..The median semen-to-plasma ratio of raltegravir concentration was 1.42 (range, 0.52 to 6.66), indicating good although variable levels of drug penetration of raltegravir in the seminal compartment...
  32. doi request reprint The effects of a maintenance therapy with peg-interferon alpha-2a on liver fibrosis in HIV/HCV co-infected patients: a randomized controlled trial
    Jean Marc Chapplain
    Department of Infectious Diseases, Rennes University Hospital, Rennes 1 University, Rennes, France
    J Infect 67:313-21. 2013
    ..We hypothesized that, in Human Immunodeficiency Virus and Hepatitis C Virus (HIV/HCV) co-infected patients who did not respond to peg-interferon and ribavirin, a maintenance therapy with peg-interferon could induce fibrosis regression...
  33. doi request reprint Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
    Jean Michel Molina
    Department of Infectious Diseases, Saint Louis Hospital, AP HP, Paris University of Paris Diderot, Paris 7, France
    Lancet 372:646-55. 2008
    ..We compared these two combinations directly in treatment-naive patients...
  34. doi request reprint Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial)
    Sebastien Gallien
    Assistance Publique Hopitaux de Paris, Hopital Saint Louis, Department of Infectious Diseases, University of Paris Diderot Paris 7, Paris, France
    J Antimicrob Chemother 66:184-91. 2011
    ..once-daily combinations of efavirenz and two nucleoside analogues are recommended for the treatment of HIV infection. Long-term efficacy and safety data are scarce for the combination of efavirenz, emtricitabine and didanosine...
  35. pmc Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients
    Constance Delaugerre
    Laboratoire de Virologie, Hôpital Saint Louis APHP, Paris, France
    PLoS ONE 7:e36673. 2012
    ..Our objective was to determine the emergence and evolution of DRAM during LLV in HIV-1-infected patients while receiving antiretroviral therapy (ART)...
  36. pmc Survival trends in critically ill HIV-infected patients in the highly active antiretroviral therapy era
    Isaline Coquet
    Service de Reanimation Medicale, AP HP, Hopital Saint Louis, 1 avenue Claude Vellefaux, Université Paris 7 Paris Diderot, UFR de Medecine, 75010 Paris, France
    Crit Care 14:R107. 2010
    ..Our objective was to assess whether highly active ART was associated with improved survival in critically ill HIV-infected patients...
  37. ncbi request reprint Risk factors for acute liver enzyme abnormalities in HIV-hepatitis B virus-coinfected patients on antiretroviral therapy
    Olivia Chauvel
    AP HP, Hopital Saint Antoine, Service de Maladies Infectieuses et Tropicales, Paris, France
    Antivir Ther 12:1115-26. 2007
    ..Little is known about the prognostic factors of acute liver enzyme variations in HIV-hepatitis B virus (HBV)-coinfected patients...
  38. doi request reprint High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients
    Victoire de Lastours
    Infectious Diseases Department, St Louis Hospital, APHP and Sorbonne Paris Cité, University Paris Diderot, Paris, France
    J Antimicrob Chemother 68:1850-6. 2013
    ..Atazanavir has been associated with kidney stones and renal failure. We measured urine and plasma concentrations of recent protease inhibitors (PIs) and searched for PI crystals in the urine of asymptomatic patients...
  39. doi request reprint AIDS-related Kaposi's sarcoma can occur during peginterferon-α and ribavirin therapy for chronic hepatitis C infection
    Victoire de Lastours
    1Infectious Diseases Department, Assistance Publique Hopitaux de Paris APHP, Hopital Saint Louis, Paris, France
    J Int Assoc Physicians AIDS Care (Chic) 11:9-11. 2012
    ..Before the arrival of highly active antiretroviral therapy (HAART), interferon α has been used successfully to treat AIDS-related Kaposi's sarcoma (KS). Peginterferon-α (pegIFN-α) may still be used successfully in refractory KS...
  40. doi request reprint Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + n
    Cathia Soulie
    Université Pierre et Marie Curie Paris, UMR S 943, INSERM, U943, Paris, France
    AIDS 23:1605-8. 2009
    ..The NNRTI + protease inhibitor strategy should not be recommended as an antiretroviral first-line regimen, particularly in patients with high viral load at baseline...
  41. ncbi request reprint Once-daily administration of antiretrovirals: pharmacokinetics of emerging therapies
    Anne Marie Taburet
    Clinical Pharmacy, Hospital Bicetre, Assistance Publique Hopitaux de Paris, France
    Clin Pharmacokinet 42:1179-91. 2003
    ..Preliminary results from these small pilot studies suggest that once-daily administration of antiretrovirals is a feasible approach. Large comparative trials are needed before the real benefits of such a strategy can be fully assessed...
  42. pmc Clinical and resistance consequences of misquantification of plasma and cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) RNA in samples from an HIV-1 subtype G-infected patient
    Constance Delaugerre
    Department of Virology, Saint Louis Hospital, 1 avenue Claude Vellefaux, 75010 Paris, France
    J Clin Microbiol 47:3763-4. 2009
    ..We report a case of underquantification of HIV type 1 (HIV-1) RNA in plasma and cerebrospinal fluid from an HIV-1 subtype G-infected woman, leading to delayed diagnosis of HIV encephalitis and to the emergence of drug resistance...
  43. ncbi request reprint Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients
    Aurélie Barrail-Tran
    AP HP, Hospital Bicetre, Paris, France
    AIDS 24:2581-3. 2010
    ..118 and 3837 vs. 2241 ng/ml) and darunavir area under the curve (AUC(12h)) (50 083 vs. 36 277 ng h/ml). All pharmacokinetic parameters appeared to be highly variable regardless to the addition of etravirine...
  44. doi request reprint Quality of travel health advice in a French travel medicine and vaccine center: a prospective observational study
    Marie Anne Bouldouyre
    Department of Infectious Diseases, Hospital Saint Louis, Paris, France
    J Travel Med 19:76-83. 2012
    ..The number of international trips undertaken by French citizens is rising and we wished to assess the appropriateness of advices given to travelers in a vaccine and travel medicine center in France...
  45. pmc Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis
    Juliette Pavie
    Service d hématologie greffe de moelle, Hopital Saint Louis, Paris, France
    J Clin Microbiol 43:4902-4. 2005
    ..Prolonged use of these new antifungal agents may increase the risk of the emergence of resistant organisms...
  46. ncbi request reprint Fumagillin treatment of intestinal microsporidiosis
    Jean Michel Molina
    Department of Infectious Diseases, Hôpital Saint Louis and University of Paris VII, Paris, France
    N Engl J Med 346:1963-9. 2002
    ..Intestinal microsporidiosis due to Enterocytozoon bieneusi is a cause of chronic diarrhea, malabsorption, and wasting in immunocompromised patients. Currently, there is no effective treatment...
  47. ncbi request reprint Emtricitabine: a novel nucleoside reverse transcriptase inhibitor
    Jean Michel Molina
    Hôpital Sant Louis, Paris, France
    Drugs Today (Barc) 41:241-52. 2005
    ..The now available combination of emtricitabine with tenofovir in the same pill makes it a very attractive backbone combination to use in conjunction with other antiretroviral drugs...
  48. pmc Development of a real-time PCR assay for quantitative detection of Encephalitozoon intestinalis DNA
    Jean Menotti
    Laboratory of Parasitology Mycology, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, and Faculté de Médecine Lariboisière Saint Louis, Universite Paris VII, Paris, France
    J Clin Microbiol 41:1410-3. 2003
    ..intestinalis DNA in blood and serum. We conclude that real-time PCR is a valuable tool for quantitation of E. intestinalis burden in clinical specimens...
  49. ncbi request reprint Impact of chronic hepatitis C and/or D on liver fibrosis severity in patients co-infected with HIV and hepatitis B virus
    Karine Lacombe
    INSERM, UMR S707, Paris, F 75012, France
    AIDS 21:2546-9. 2007
    ..02, 95% CI = 1.03-97.42 for HBV-HCV-HDV, compared to OR = 1.76, 95% CI = 0.50-6.17 for HBV alone]. Co-treatment of other multiple viral hepatitis infections should also be taken into consideration, especially in the case of chronic HDV...
  50. pmc Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial)
    Charlotte Charpentier
    Laboratoire de Virologie, Assistance Publique Hopitaux de Paris AP HP, Groupe Hospitalier Bichat Claude Bernard, HUPNVS, Universite Paris Diderot, Paris 7, PRES Sorbonne Paris Cité, EA4409, Paris, France
    PLoS ONE 8:e53621. 2013
    ..The aim of this virological sub-study of the ANRS 139 TRIO trial was to assess: (i) the evolution of HIV-1 DNA over the first year; and (ii) the association between baseline HIV-1 DNA and virological outcome...
  51. doi request reprint Prevalence of antibodies and RNA genome of hepatitis E virus in a cohort of French immunocompromised
    Sarah Maylin
    Virology Dpt, INSERM U941 Paris 7 Diderot University, Saint Louis Hospital APHP, Paris, France
    J Clin Virol 53:346-9. 2012
    ..Recently, cases of chronic hepatitis E have been identified in immunocompromised patients...
  52. doi request reprint Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial
    Nathalie de Castro
    Department of Infectious Diseases, Assistance Publique Hopitaux de Paris, Saint Louis Hospital and University of Paris VII Denis Diderot, Paris, France
    Clin Infect Dis 49:1259-67. 2009
    ..We conducted a prospective, randomized, open-label trial to compare the antiviral efficacy and safety of a switch to raltegravir with the efficacy and safety of continuing enfuvirtide...
  53. doi request reprint Varicella-zoster virus-specific cell-mediated immune responses in HIV-infected adults
    Nathalie de Castro
    Department of Infectious Diseases, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, University of Paris Denis Diderot, France
    AIDS Res Hum Retroviruses 27:1089-97. 2011
    ..HIV-infected patients with a history of AIDS or low CD4 cell counts have impaired VZV-specific CMI responses, and remain at risk for herpes zoster...
  54. doi request reprint Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adults
    Claire Rabian
    Laboratoire d Immunologie et d Histocompatibilité, St Louis Hospital, Paris, France
    Clin Infect Dis 50:1174-83. 2010
    ..CD4 T cell responses specific to the diphtheria-derived carrier protein CRM(197) were evaluated...
  55. doi request reprint Case report: Cure of chronic infection with hepatitis C virus after 6 weeks of peg-interferon and ribavirin in a patient co-infected with HIV
    Anne Rachline
    Department of Infectious Diseases, Hopital Saint Louis, Paris, France
    J Med Virol 82:1150-1. 2010
    ..This report describes a patient co-infected with HCV genotype 2 and HIV who discontinued HCV therapy after 6 weeks because of adverse events and had a sustained virologic response...
  56. doi request reprint CD8 encephalitis in HIV-infected patients receiving cART: a treatable entity
    Francois Xavier Lescure
    Service des Maladies Infectieuses et Tropicales, AP HP, Hopital Tenon, Paris, France
    Clin Infect Dis 57:101-8. 2013
    ..New acute and chronic neurological complications continue to be reported...
  57. pmc Effects of chemical and physical agents on viability and infectivity of Encephalitozoon intestinalis determined by cell culture and flow cytometry
    Maud Santillana-Hayat
    Parasitology Mycology Laboratory, Department of Infectious Diseases, Saint Louis Hospital, AP HP and EA 3520, University of Paris 7, France
    Antimicrob Agents Chemother 46:2049-51. 2002
    ..Surfanios and benzalkonium chloride, disinfectants currently used in the hospital, were remarkably efficient in destroying spore viability and infectivity...
  58. ncbi request reprint Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus
    Alexandre Karras
    Service de Nephrologie, Hopital Saint Louis, 75475 Paris Cedex 10, France
    Clin Infect Dis 36:1070-3. 2003
    ..Patients receiving tenofovir must be monitored closely for early signs of tubulopathy (glycosuria, acidosis, mild increase in the plasma creatinine level, and proteinuria)...
  59. pmc Sensitivity of five rapid HIV tests on oral fluid or finger-stick whole blood: a real-time comparison in a healthcare setting
    Juliette Pavie
    Service des Maladies Infectieuses et Tropicales, Hopital Saint Louis, Universite Paris Diderot, Paris, France
    PLoS ONE 5:e11581. 2010
    ..Several HIV rapid tests are now licensed in Europe but their sensitivity on total blood and/or oral fluid in routine healthcare settings is not known...
  60. doi request reprint Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial
    Claire Gozalo
    Department of Molecular Genetics, Pharmacogenetics and Hormonology, Assistance Publique Hopitaux de Paris, Bicetre Hospital, France
    Basic Clin Pharmacol Toxicol 109:513-20. 2011
    ....
  61. doi request reprint Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trial
    Matthieu Lafaurie
    Department of Infectious Diseases, Saint Louis Hospital, University of Paris 7, INSERM U897, 1 avenue Claude Vellefaux 75010 Paris, France
    J Antimicrob Chemother 62:1122-9. 2008
    ..However, it is unclear whether patients tolerating long-term zidovudine-containing regimens will benefit from a switch to non-zidovudine-containing regimens...
  62. ncbi request reprint Prevalence of intestinal parasites including microsporidia in human immunodeficiency virus-infected adults in Cameroon: a cross-sectional study
    Claudine Sarfati
    Laboratory of Parasitology and Department of Infectious Diseases, Saint Louis Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    Am J Trop Med Hyg 74:162-4. 2006
    ..parvum in six patients, and Isospora belli in three patients. All E. bieneusi isolates tested belonged to the same genotype. The prevalence of opportunistic protozoa among patients with CD4 cell counts less than 50/mm(3) was 32%...
  63. doi request reprint Severe acute renal failure in an HIV-infected patient after only 2 weeks of tenofovir-based antiretroviral therapy
    Juliette Pavie
    Department of Infectious Diseases, Saint Louis Hospital, University of Paris Diderot, France
    AIDS Patient Care STDS 25:457-60. 2011
    ..Although severe renal toxicity due to tenofovir is rare, patients receiving tenofovir must be monitored closely for renal dysfunction especially during the first weeks of tenofovir therapy...
  64. pmc Pressure from TRIM5α contributes to control of HIV-1 replication by individuals expressing protective HLA-B alleles
    Clémence Granier
    INSERM U941, Paris, France
    J Virol 87:10368-80. 2013
    ....
  65. pmc Characterization of binding of raltegravir to plasma proteins
    Caroline Barau
    Assistance Publique, Hopitaux de Paris, Hopital Bicetre, Hôpitaux Universitaires Paris Sud, Service de Pharmacie Clinique, Paris, France
    Antimicrob Agents Chemother 57:5147-50. 2013
    ..RAL did not bind to AAG but bound to nonsaturable, low-affinity albumin sites with an n (number of sites) · Ka product of 9.8 × 10(2) liters/mol. A pH increase of 0.2 U led to a 2% increase in the bound fraction. ..
  66. ncbi request reprint Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease
    Ségolène Neuville
    Department of Infectious Diseases, Saint Louis Hospital, University of Paris, AP HP, Paris, France
    Am J Hematol 79:337-9. 2005
    ..Clinical and virologic relapses with increased blood human herpesvirus-8 DNA levels occurred in both patients 4 and 24 weeks later and were associated with a worsening of Kaposi sarcoma...
  67. doi request reprint Iatrogenic Cushing's syndrome in HIV-infected patients receiving ritonavir and inhaled fluticasone: description of 4 new cases and review of the literature
    Nadia Valin
    Service de Maladies Infectieuses et Tropicales, APHP, Hopital Saint Louis, 75010 Paris, France
    J Int Assoc Physicians AIDS Care (Chic) 8:113-21. 2009
    ....
  68. ncbi request reprint Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection
    Philippe Flandre
    Unité INSERM U720, BP 335 75625, Paris, France
    J Infect Dis 195:392-8. 2007
    ..We investigated the relationship between human immunodeficiency virus (HIV) phenotypic susceptibility to didanosine and the antiviral activity of didanosine (ddI) in the JAGUAR study...
  69. pmc Inhibitory activity of human immunodeficiency virus aspartyl protease inhibitors against Encephalitozoon intestinalis evaluated by cell culture-quantitative PCR assay
    Jean Menotti
    Laboratoire de Parasitologie Mycologie, Hopital Saint Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
    Antimicrob Agents Chemother 49:2362-6. 2005
    ..intestinalis growth at concentrations that are achievable in vivo and that the real-time quantitative PCR assay that we used is a valuable tool for the in vitro assessment of the activities of drugs against E. intestinalis...
  70. doi request reprint Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials
    Christine Katlama
    Universite Pierre et Marie Curie, Paris VI and Hôpital Pitié Salpêtrière, Paris, France
    AIDS 23:2289-300. 2009
    ....
  71. doi request reprint Severe peripheral neuropathy following HAART initiation in an HIV-infected patient with leprosy
    Juliette Pavie
    Department of Infectious Diseases, Saint Louis Hospital and University of Paris Diderot, Paris, France
    J Int Assoc Physicians AIDS Care (Chic) 9:232-5. 2010
    ..Physicians in charge of HIV-infected patients originating from countries endemic for leprosy should be aware of this risk of leprosy-associated IRIS when starting HAART...
  72. doi request reprint Comparative RNA quantification of HIV-1 group M and non-M with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott Real-Time HIV-1 PCR assays
    Jean Marie Sire
    Laboratoire de Virologie, Hôpital Saint Louis AP HP, INSERM U941, Universite Paris Diderot, Paris, France
    J Acquir Immune Defic Syndr 56:239-43. 2011
    ..A new version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 assay (CA/CTM v2.0) has been introduced to overcome the underquantification observed with the first version...
  73. ncbi request reprint A case report of adenovirus-related acute interstitial nephritis in a patient with AIDS
    Elodie Mazoyer
    Service de Nephrologie, Hopital Saint Louis, AP HP, Paris, France
    Am J Kidney Dis 51:121-6. 2008
    ..This case illustrates another cause of acute kidney disease in very immunosuppressed patients with AIDS, probably underdiagnosed...
  74. pmc JC virus variant associated with cerebellar atrophy in a patient with AIDS
    Damien Roux
    Laboratoire de Microbiologie, Hopital Saint Louis, 1 avenue Claude Vellefaux, 75010 Paris, France
    J Clin Microbiol 49:2196-9. 2011
    ..Our data underline the importance of searching for JCV in HIV-infected patients with cerebellar disorders and suggest that mutations in the regulatory region may be involved in cerebellar degeneration...
  75. pmc I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y
    Jerome Legoff
    University Paris Diderot, Sorbonne Paris Cité, Paris, France
    PLoS ONE 7:e37095. 2012
    ..A new mutation I223R in the neuraminidase (NA) of H1N1pdm09 virus has been reported along with H275Y in immunocompromised patients. The aim of this study was to determine the impact of I223R on oseltamivir and zanamivir susceptibility...
  76. pmc Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition
    Victoire de Lastours
    Infectious Diseases Department, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, 1 avenue Claude Vellefaux, 75010 Paris, France
    Antimicrob Agents Chemother 55:4905-7. 2011
    ..Mean ratios of saliva/plasma concentration were 3% (±4%) and 86.9% (±124%) for TFV and FTC, respectively. Tenofovir disoproxil fumarate (TDF) should be used in combination with FTC to prevent oral acquisition of HIV...
  77. ncbi request reprint Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS
    Emmanuelle Boulanger
    Department of Clinical Immunology, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, 1 avenue Claude Vellefaux, 75 475 Paris Cedex 10, France
    J Clin Oncol 23:4372-80. 2005
    ..The prognosis is poor, with reported median survival time shorter than 6 months. To date, no prognostic factor has been identified in this subset of lymphoma...
  78. pmc Fully automated quantification of cytomegalovirus (CMV) in whole blood with the new sensitive Abbott RealTime CMV assay in the era of the CMV international standard
    Nathalie Schnepf
    Universite Paris Diderot, PRES Sorbonne Paris Cité, INSERM U941, APHP, Microbiology Laboratory, Hopital Saint Louis, Paris, France
    J Clin Microbiol 51:2096-102. 2013
    ..Our results highlight the need for careful validation of conversion factors provided by the manufacturers for the WHO IS in WB to allow future comparison of results obtained with different assays...
  79. ncbi request reprint Herpes simplex virus type 2 as a cause of severe meningitis in immunocompromised adults
    Herve Mommeja-Marin
    Department of Infectious Diseases, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, France
    Clin Infect Dis 37:1527-33. 2003
    ..HSV-2 can cause severe meningitis in immunocompromised patients. Early recognition and treatment might improve the outcome of such infections...
  80. doi request reprint Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136)
    P Yeni
    University Hospital Bichat, Paris, France
    HIV Med 10:116-24. 2009
    ..This phase IIb study explored the antiviral activity and safety of the investigational CC chemokine receptor 5 (CCR5) antagonist aplaviroc (APL) in antiretroviral-naïve patients harbouring R5- or R5X4-tropic virus...
  81. ncbi request reprint Efficacy and safety of once-daily regimens in the treatment of HIV infection
    Jean Michel Molina
    Department of Infectious Diseases, Assistance Publique Hopitaux de Paris, Hopital Saint Louis, Universite Paris Diderot, Paris 7, France
    Drugs 68:567-78. 2008
    ..Such regimens are likely to improve patient adherence because they are simpler and more convenient than earlier therapeutic regimens...
  82. ncbi request reprint Severe Actinobacillus ureae meningitis in an immunocompromised patient: report of one case and review of the literature
    Nathalie de Castro
    Infectious Diseases Department, APHP Hôpital Saint Louis, Paris, France
    Scand J Infect Dis 39:1076-9. 2007
    ..Risk factors, clinical outcome and treatment of Actinobacillus ureae infections are discussed. Actinobacillus ureae may behave as an opportunistic pathogen causing severe infections in immunocompromised patients...
  83. doi request reprint Pandemic Influenza A (H1N1) Infection among HIV-Infected Adults in France
    Mathieu Tourdjman
    1Service des Maladies Infectieuses, Hopital Saint Louis, Paris, France
    J Int Assoc Physicians AIDS Care (Chic) 10:229-31. 2011
    ..No severe influenza infection was observed, but a high frequency of secondary bacterial pneumonia is reported among pneumococcal unvaccinated patients...
  84. pmc Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure
    Pierre Delobel
    Service des Maladies Infectieuses et Tropicales, Hopital Purpan, Toulouse, France
    PLoS ONE 6:e21655. 2011
    ..04). Thus ultrasensitive methods could prove more useful than direct sequencing for predicting treatment failure in some patients. However the presence of minor NNRTI-resistant viruses need not always result in virological escape...
  85. doi request reprint Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials
    Christine Katlama
    Universite Pierre et Marie Curie, Paris 6, France
    Antivir Ther 15:1045-52. 2010
    ..The 96-week efficacy and safety of the non-nucleoside reverse transcriptase inhibitor (NNRTI) etravirine were evaluated in the Phase III DUET trials...
  86. doi request reprint Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial
    Odile Launay
    Paris Descartes University, France
    JAMA 305:1432-40. 2011
    ..Alternative schedules more immunogenic than the standard hepatitis B vaccine regimen are needed in patients with human immunodeficiency virus 1 (HIV-1) infection...
  87. pmc Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
    Antimicrob Agents Chemother 52:4251-7. 2008
    ....
  88. pmc Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment
    Yves Levy
    1INSERM U955, Universite Paris 12, and Assistance Publique Hôpitaux de Paris AP HP, Groupe Henri Mondor Albert Chenevier, Immunologie Clinique, Creteil, France
    J Clin Invest 119:997-1007. 2009
    ..Therefore, patients may benefit from intermittent therapy with IL-7 in combination with c-ART...
  89. doi request reprint Reactive haemophagocytic syndrome in 58 HIV-1-infected patients: clinical features, underlying diseases and prognosis
    Laurence Fardet
    Hopital Saint Antoine, France
    AIDS 24:1299-306. 2010
    ..To describe features of reactive haemophagocytic syndrome (RHS) in HIV-1-infected adult patients. To compare characteristics of patients with malignancy-associated RHS and infection-associated RHS...
  90. pmc High burden of non-influenza viruses in influenza-like illness in the early weeks of H1N1v epidemic in France
    Nathalie Schnepf
    Universite Paris Diderot, Sorbonne Paris Cité, Microbiology Department, Saint Louis Hospital, APHP, Paris, France
    PLoS ONE 6:e23514. 2011
    ..Clinical observations are of little help to recognise myxovirus infection and implement appropriate prevention measures. The limited use of molecular tools underestimates the role of other common pathogens...
  91. doi request reprint Restoration of Toxoplasma gondii-specific immune responses in patients with AIDS starting HAART
    Andre Furco
    Department of Infectious Diseases, Saint Louis Hospital, Assistance Publique Hôpitaux de Paris and University of Paris 7, Paris Diderot, Paris, France
    AIDS 22:2087-96. 2008
    ..To study the kinetics and identify factors associated with Toxoplasma-specific immune responses in patients with AIDS starting antiretroviral therapy...
  92. pmc Detection of extensive cross-neutralization between pandemic and seasonal A/H1N1 Influenza Viruses using a pseudotype neutralization assay
    Beatrice Labrosse
    Institut Universitaire d Hematologie, Universite Paris Diderot, Paris, France
    PLoS ONE 5:e11036. 2010
    ..In particular, the extent that previous infection or vaccination by seasonal A/H1N1 viruses can elicit protective immunity against pandemic A/H1N1 is unclear...
  93. doi request reprint Etiologies and outcome of acute respiratory failure in HIV-infected patients
    Francois Barbier
    Medical ICU and Infectious Disease Department, AP HP, Hopital Saint Louis, 1 avenue Claude Vellefaux, 75010, Paris, France
    Intensive Care Med 35:1678-86. 2009
    ..To assess the etiologies and outcome of acute respiratory failure (ARF) in HIV-infected patients over the first decade of combination antiretroviral therapy (ART) use...
  94. ncbi request reprint Aseptic meningitis associated with intravenous administration of dexchlorpheniramine
    Matthieu Lafaurie
    Service des Maladies Infectieuses et Tropicales, Hopital Saint Louis, 1, avenue Claude Vellefaux, 75475 Paris Cedex 10
    Ann Med Interne (Paris) 154:179-80. 2003
    ..We describe today a very unusual reaction on intravenous dexchlorpheniramine with this case of aseptic meningitis...
  95. doi request reprint Acute kidney disease due to immune reconstitution inflammatory syndrome in an HIV-infected patient with tuberculosis
    Carine Salliot
    Department of Infectious Diseases, Hopital Saint Louis, Paris, France
    J Int Assoc Physicians AIDS Care (Chic) 7:178-81. 2008
    ..All published case reports of IRIS revealed by acute renal failure in HIV-infected patients are also reviewed...
  96. doi request reprint Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients
    Julie Bottero
    INSERM UMR S707, Paris, France
    J Hepatol 50:1074-83. 2009
    ..The aim of this study was to compare the performance of 11 biochemical scores to estimate liver fibrosis in HIV/HBV co-infection...
  97. ncbi request reprint Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients
    Matthieu Lafaurie
    Service des Maladies Infectieuses et Tropicales, Hopital Saint Louis, Paris, France
    J Acquir Immune Defic Syndr 38:393-8. 2005
    ..This study assessed the safety and efficacy of intradermal injections of polylactic acid (PLA) in patients with facial lipoatrophy under antiretroviral therapy...
  98. doi request reprint Failure of atovaquone/proguanil to prevent Plasmodium ovale malaria in traveler returning from Cameroon
    Sebastien Gallien
    Department of Tropical and Infectious Diseases, Saint Louis University Hospital, 75475 Paris Cedex 10, France
    Travel Med Infect Dis 6:128-9. 2008
    ..Travelers returned from risk areas with symptoms suggestive of malaria, should not have the diagnosis of P. ovale (or P. vivax) infection discounted, despite a history of compliance with a standard chemoprophylactic regimen...
  99. ncbi request reprint Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome
    Marie Robin
    Service d Hematologie, Greffe, Paris, France
    Haematologica 92:1254-7. 2007
    ..Risk factors for dAdV in unrelated HSCT recipients were previous Fanconi disease (p=0.03) and GVHD (p=0.02) in children, and cord blood source of stem cells (p=0.029) and GVHD (0.024) in adults...
  100. doi request reprint Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial
    Claudine Duvivier
    AP HP, Groupe Hospitalier Pitie Salpetriere, Service de Maladies Infectieuses et Tropicales, Paris F 75013, France
    J Antimicrob Chemother 62:797-808. 2008
    ..The aim of this study was to evaluate the impact on body fat of nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimens compared with NRTI-containing therapy in HIV-1-infected antiretroviral (ARV)-naive patients...
  101. doi request reprint Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
    Gerd Fatkenheuer
    Universitätsklinik Köln, Cologne, Germany
    N Engl J Med 359:1442-55. 2008
    ....